Cancer Letters
Volume 224, Issue 1 , Pages 53-65 , 16 June 2005

Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression

  • Monica Notarbartolo

      Affiliations

    • Dipartimento di Scienze Farmacologiche, Università di Palermo, Via del Vespro 129, 90127 Palermo, Italy
    • ,
  • Paola Poma

      Affiliations

    • Dipartimento di Scienze Farmacologiche, Università di Palermo, Via del Vespro 129, 90127 Palermo, Italy
    • ,
  • Daniela Perri

      Affiliations

    • Dipartimento di Scienze Farmacologiche, Università di Palermo, Via del Vespro 129, 90127 Palermo, Italy
    • ,
  • Luisa Dusonchet

      Affiliations

    • Dipartimento di Scienze Farmacologiche, Università di Palermo, Via del Vespro 129, 90127 Palermo, Italy
    • ,
  • Melchiorre Cervello

      Affiliations

    • IBIM C.N.R. ‘Alberto Monroy’, Via U. La Malfa 153, 90146 Palermo, Italy
    • ,
  • Natale D'Alessandro

      Affiliations

    • Dipartimento di Scienze Farmacologiche, Università di Palermo, Via del Vespro 129, 90127 Palermo, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 91 655 3258; fax: +39 91 655 3249.

Received 16 March 2004 ,Revised 15 September 2004 ,Accepted 20 October 2004.

References 

  1. Falkson G, MacIntyre JM, Moertel CG. Primary liver cancer. Cancer. 1994;54:977–980
  2. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 2000;31:1080–1085
  3. Takehara T, Liu X, Fujimoto J, Friedman SL, Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology. 2001;34:55–61
  4. Ikeguchi M, Hirooka Y, Kaibara N. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer. 2002;95:1938–1945
  5. Shiraki K, Sugimoto K, Yamanaka Y, Yamaguchi Y, Saitou Y, Ito K, et al. Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int. J. Mol. Med. 2003;12:705–708
  6. Notarbartolo M, Cervello M, Giannitrapani L, Meli M, Poma P, Dusonchet L, et al. Expression of the IAPs and alternative splice variants in hepatocellular carcinoma tissues and cells. Ann. NY Acad. Sci. 2004;1028:289–293
  7. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999;13:239–252
  8. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. 2000;10:1359–1366
  9. Kasof GM, Gomes BC. Livin, a novel inhibitor-of-apoptosis (IAP) family member. J. Biol. Chem. 2001;266:3238–3246
  10. Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl Acad. Sci. USA. 2001;98:8662–8667
  11. MacFarlane M, Merrison W, Bratton SB, Cohen GM. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J. Biol. Chem. 2002;277:36611–36616
  12. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680–1683
  13. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079–4086
  14. Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B, et al. Activation of NF-kappaB, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J. Hepatol. 2002;37:63–71
  15. Chiao PJ, Na R, Niu J, Sclabas GM, Dong Q, Curley SA. Role of Rel/NF-kappaB transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer. 2002;95:1696–1705
  16. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology. 1999;29:688–696
  17. Abou-Elella A, Gramlich T, Fritsch C, Gansler T. c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Mod. Pathol. 1996;9:95–98
  18. Duyao MP, Buckler AJ, Sonesheim GE. Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter. Proc. Natl Acad. Sci. USA. 1990;87:4727–4731
  19. Sevilla L, Zaldumbide A, Pognonec P, Boulukos KE. Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFkappaB, STAT and AP1 transcription factor families. Histol. Histopathol. 2001;16:595–601
  20. Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis. 2003;24:1269–1279
  21. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363–398
  22. Mitchell TM. Lett. Cancer Res. 2003;63:5165–5166
  23. Berenbaum MC. What is synergy?. Pharmacol. Rev. 1989;41:93–141
  24. Wang CY, Mayo MW, Baldwin AS. TNF and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science (Washington DC). 1996;274:784–787
  25. Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Pu YS. Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21WAF1/CIP1 and C/EBPβ expressions and suppressing NF-kB activation. Prostate. 2002;51:211–218
  26. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M, et al. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kB (NF-kB), and its attenuation by tamoxifen, dexamethasone and curcumin in carcinoma cells. Biochem. Pharmacol. 2002;63:1709–1716
  27. Ashikawa K, Shishodia S, Fokt I, Priebe W, Aggarwal BB. Evidence that activation of nuclear factor-kB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem. Pharmacol. 2004;67:353–364
  28. Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ. Dietary curcumin inhibits chemotherapy-induced apoptosis in model of human breast cancer. Cancer Res. 2002;62:3868–3875
  29. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, et al. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis. 2003;24:1199–1208
  30. Bush JH, Cheung KJJ, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp. Cell Res. 2001;271:301–314
  31. Bielak-Zmijewska A, Piwocka K, Magalska A, Sikora E. P-glycoprotein expression does not change the apoptotic pathway induced by curcumin in HL-60 cells. Cancer Chemother. Pharmacol. 2004;53:179–185
  32. Chan MM, Fong D, Soprano KJ, Holmes WF, Heverling H. Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J. Cell Physiol. 2003;194:63–70
  33. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett. 2001;172:111–118
  34. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene. 2001;20:7597–7609
  35. Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, et al. Human ovarian cancer and cisplatin resistance: possible role of apoptosis proteins. Endocrinology. 2001;142:370–380
  36. Matsumiya T, Imaizumi T, Yoshida H, Kimura H, Satoh K. Cisplatin inhibits the expression of X-chromosome-linked inhibitor of apoptosis in an oral carcinoma cell line. Oral Oncol. 2001;37:296–300
  37. Notarbartolo M, Cervello M, Dusonchet L, Cusimano A, D'Alessandro N. Resistance to diverse apoptotic triggers in multidrug resistant HL-60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (Inhibitory of Apoptosis Proteins). Cancer Lett. 2002;180:91–101
  38. Zhou M, Gu L, Li F, Zu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J. Pharmacol. Exp. Ther. 2002;303:124–131
  39. Hu Y, Bally M, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol. Cancer Ther. 2003;2:641–649
  40. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol. Cell. 2004;13:853–865

PII: S0304-3835(04)00875-4

doi: 10.1016/j.canlet.2004.10.051

Cancer Letters
Volume 224, Issue 1 , Pages 53-65 , 16 June 2005

Article Tools

* Image Usage & Resolution